MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.atherosclerosis.2016.08.023

Медицинская библиотека · Atherosclerosis · 2016

The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency.

Steinhagen-Thiessen Elisabeth, Stroes Erik, Soran Handrean, Johnson Colin, Moulin Philippe, Iotti Giorgio, Zibellini Marco, Ossenkoppele Bas, Dippel Michaela, Averna Maurizio R, GENIALL Investigators

СтатьяОбзорПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

UNLABELLED: A good understanding of the natural history of rare genetic lipid disorders is a pre-requisite for successful patient management. Disease registries have been helpful in this regard. Lipoprotein Lipase Deficiency (LPLD) is a rare, autosomal-recessive lipid disorder characterized by severe hypertriglyceridemia and a very high risk for recurrent acute pancreatitis, however, only limited data are available on its natural course. Alipogene tiparvovec (Glybera®) is the first gene therapy to receive Marketing Authorization in the European Union; GENIALL (GENetherapy In the MAnagement of Lipoprotein Lipase Deficiency), a 15-year registry focusing on LPLD was launched in 2014 as part of its Risk Management Plan. The aim of this publication is to introduce the GENIALL Registry within a structured literature review of registries in rare genetic lipid disorders. A total of 11 relevant initiatives/registries were identified (homozygous Familial Hypercholesterolemia (hoFH) [n = 5]; LPLD [n = 1]; Lysosomal Acid Lipase Deficiency [LALD, n = 1], detection of mutations in genetic lipid disorders [n = 4]). Besides one product registry in hoFH and the LALD registry, all other initiatives are local or country-specific. GENIALL is the first global prospective registry in LPLD that will collect physician and patient generated data on the natural course of LPLD, as well as long-term outcomes of gene therapy.

CONCLUSION

There is a limited number of international initiatives focusing on the natural course of specific rare genetic lipid disorders. The GENIALL LPLD Registry could be the first step towards a future broader global initiative that collects data related to familial chylomicronemia syndrome and their underlying genetic causes.

Для цитирования: Steinhagen-Thiessen Elisabeth, Stroes Erik, Soran Handrean, Johnson Colin, Moulin Philippe, Iotti Giorgio, Zibellini Marco, Ossenkoppele Bas, Dippel Michaela, Averna Maurizio R, GENIALL Investigators. The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency.. Atherosclerosis. 2016. DOI: 10.1016/j.atherosclerosis.2016.08.023.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.